Researchers are one step closer to developing eye drops to treat age-related macular degeneration (AMD)
Scientists at the University of Birmingham, UK, are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by disagreeable injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drugs as eye drops.
Laboratory research published last year in Investigative Ophthalmology & Visual Science (IOVS) showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
These studies, also published in IOVS, demonstrated that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as the Spring of 2019.
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent R&D programmes and clinical trials. We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
Dr de Cogan commented: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye. From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
Now that we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured R&D programme that should bring concrete benefits to people with AMD and other eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD. They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Ruth Ashton, University of Birmingham Enterprise, on +44 (0)121 414 6681, +44 7989 558041, or the University Press Office out of hours on +44 (0)7789 921165.
About the University of Birmingham
The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 5,000 international students from over 150 countries. The University of Birmingham’s patented technologies are showcased on the IN-PART partnering website, and on the Midlands Innovation website.
About the research
De Cogan et al (2018). ‘Topical Treatment for AMD: Non-Invasive Delivery and Efficacy of Ranibizumab and Bevacizumab in Rabbit and Porcine Eyes.’ Investigative Ophthalmology & Visual Science, vol 59, issue 9, abstract 1439.
The research was carried out by the Institute of Microbiology and Infection and School of Chemistry at the University of Birmingham, Warwick Hospital, and the Centre for Experimental Medicine, Queens University, Belfast. It was supported by a Wellcome Trust Pathfinder Award, 109674/Z/15/Z and the University of Birmingham.
The previous study, published in March 2017 was: De Cogan et al (2017). ‘Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides.’ Investigative Ophthalmology & Visual Science. DOI:10.1167/iovs.16-20072
About Macregen, Inc.
Macregen, Inc. is dedicated to the development of transformative therapies for the preservation of eye sight and treatment for people suffering from age-related macular degeneration (AMD) and other eye diseases.
For more information about Macregen visit www.macregen.com
Enquiries about licensing, commercial partnerships and clinical trials should be directed to:
Jake Requard, Director of Business Development, Macregen, Inc.
About philanthropic giving
Macregen and the University of Birmingham are working together to secure philanthropic support to help advance and accelerate this research.
As an exempt charity under Schedule 2 of the Charities Act 1993, the University is able to receive donations from individuals, charitable Trusts and Foundations, and corporates. In addition, the University is an approved partner of the British Schools and Universities Foundation, a 501c3, that enables charitable giving from supporters based in the US.
If you would like to help us advance this research into macular degeneration visit our giving page https://your.bham.ac.uk/givetomaculardegeneration, or contact Joe McDowell in our Development team on +44 121 414 8136.